OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Tamam Abdul‐Ghani, Curtiss Puckett, Osama Migahid, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 9, pp. 1810-1818
Closed Access | Times Cited: 6
Showing 6 citing articles:
Cluster Analysis in Diabetes Research: A Systematic Review Enhanced by a Cross-Sectional Study
Binura Taurbekova, Radmir Sarsenov, Muhammad M. Yaqoob, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 10, pp. 3588-3588
Open Access
Binura Taurbekova, Radmir Sarsenov, Muhammad M. Yaqoob, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 10, pp. 3588-3588
Open Access
Etiologies underlying subtypes of long-standing type 2 diabetes
Riad Bayoumi, Muhammad H. Farooqi, Fatheya Alawadi, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0304036-e0304036
Open Access | Times Cited: 2
Riad Bayoumi, Muhammad H. Farooqi, Fatheya Alawadi, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0304036-e0304036
Open Access | Times Cited: 2
Pharmacometabolomic Approach to Investigate the Response to Metformin in Patients with Type 2 Diabetes: A Cross-Sectional Study
Khaled Naja, Najeha Anwardeen, Moustafa Al‐Hariri, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2164-2164
Open Access | Times Cited: 5
Khaled Naja, Najeha Anwardeen, Moustafa Al‐Hariri, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2164-2164
Open Access | Times Cited: 5
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials
Wolfgang Landgraf, Grégory Bigot, Brian M. Frier, et al.
Primary care diabetes (2023) Vol. 17, Iss. 4, pp. 379-385
Open Access | Times Cited: 3
Wolfgang Landgraf, Grégory Bigot, Brian M. Frier, et al.
Primary care diabetes (2023) Vol. 17, Iss. 4, pp. 379-385
Open Access | Times Cited: 3
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Wolfgang Landgraf, David R. Owens, Brian M. Frier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 503-511
Open Access | Times Cited: 1
Wolfgang Landgraf, David R. Owens, Brian M. Frier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 503-511
Open Access | Times Cited: 1
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis
Wolfgang Landgraf, David R. Owens, Brian M. Frier, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 8, pp. 1769-1784
Open Access
Wolfgang Landgraf, David R. Owens, Brian M. Frier, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 8, pp. 1769-1784
Open Access
